Program
plonmarlimab
Also written as “Plonmarlimab”, “TJ003234” and “TJ003234 injection”.
Its studies are mostly in Arthritis, Gouty · Lymphohistiocytosis, Hemophagocytic · COVID-19 · Arthritis, Rheumatoid, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| I-Mab Biopharma US | 30 open or running | phase 3since Apr 4, 2020 | Dec 28, 2018 | none ahead |
| TJ Biopharma | 32 open or running | phase 3since Sep 27, 2025 | Jun 13, 2025 | Dec 20, 2026phase 3 · NCT07208058 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 28, 2018First study: phase 1 study in Healthy Adult SubjectsNew to I-Mab Biopharma USI-Mab Biopharma US · NCT03794180 · 32 enrolled · United States
- Apr 4, 2020Phase 3 study in Coronavirus Disease 2019 COVID-19I-Mab Biopharma US · NCT04341116 · 149 enrolled · United States
- Jun 28, 2020Phase 1 study in Arthritis, RheumatoidI-Mab Biopharma US · NCT04457856 · 63 enrolled · China
- Jun 13, 2025TJ Biopharma's first study: phase 2 study in Lymphohistiocytosis, HemophagocyticNew to TJ BiopharmaTJ Biopharma · NCT07034209 · 18 enrolled · China
- Sep 27, 2025Phase 3 study in RecurrenceTJ Biopharma · NCT07208058 · 30 planned · China
- Feb 27, 2026Phase 2 study in Acute Gouty ArthritisTJ Biopharma · NCT07453004 · 170 planned · China
Ahead
- Dec 20, 2026Primary completion: phase 3 study in RecurrenceTJ Biopharma · NCT07208058
- Dec 31, 2027Primary completion: phase 2 study in Acute Gouty ArthritisTJ Biopharma · NCT07453004
TargetBeta
“A humanized immunoglobulin (Ig) G1 monoclonal antibody against the human cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), ”NCIt, by rule
“Granulocyte-macrophage colony-stimulating factor antagonist”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07453004Acute Gouty Arthritis · China | 2 | Recruiting | TJ Biopharma | Dec 31, 2027 | 170 |
| NCT07208058Recurrence · China | 3 | Recruiting | TJ Biopharma | Dec 20, 2026 | 30 |
| NCT07034209Lymphohistiocytosis, Hemophagocytic · China | 2 | Completed | TJ Biopharma | Apr 18, 2025 | 18 |
| NCT04457856Arthritis, Rheumatoid · China | 1 | UNKNOWN | I-Mab Biopharma US | Mar 2023 | 63 |
| NCT04341116Coronavirus Disease 2019 COVID-19 · United States | 3 | Completed | I-Mab Biopharma US | Feb 7, 2022 | 149 |
| NCT03794180Healthy Adult Subjects · United States | 1 | Completed | I-Mab Biopharma US | Sep 5, 2019 | 32 |
How it is read
Names in the registry
- “Plonmarlimab”, 3 entries
- “TJ003234”, 2 entries
- “TJ003234 injection”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Gouty, 1 study
- Lymphohistiocytosis, Hemophagocytic, 1 study
- COVID-19, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.